Cargando…

2404. Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement

BACKGROUND: To increase available antibiotics for local administration in total joint replacements, this study investigated TLV and VAN added to Palacos® bone cement. Mechanical properties and antimicrobial activity of eluted antibiotics on common causative orthopedic implant pathogens were assessed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bishop, Aaron, Kim, Sunjung, Squire, Matthew, Ploeg, Heidi-Lynn, Rose, Warren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253403/ http://dx.doi.org/10.1093/ofid/ofy210.2057

Ejemplares similares

Data for vancomycin elution, activity and impact on mechanical properties when incorporated into orthopedic bone cement
por: Bishop, Aaron R., et al.
Publicado: (2018)

475 Telavancin (TLV) In vitro Activity Tested Against a USA Collection of Methicillin-resistant Staphylococcus aureus (MRSA), Including a Multidrug-resistant (MDR) Subset (2011-2013)
por: Mendes, Rodrigo E., et al.
Publicado: (2014)

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
por: Rubinstein, Ethan, et al.
Publicado: (2011)

1323. Efficacy and Safety of Telavancin Compared to Vancomycin for Cystic Fibrosis Pulmonary Exacerbation in Adults
por: Shorman, Mahmoud, et al.
Publicado: (2021)

2404. Molecular Epidemiology of Clostridioides difficile in the United States, 2017
por: Paulick, Ashley, et al.
Publicado: (2019)

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Bressler, Adam M., et al.
Publicado: (2019)

High dose of vancomycin plus gentamicin incorporated acrylic bone cement decreased the elution of vancomycin
por: Li, Tao, et al.
Publicado: (2019)

Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)

Chemical Stability of Telavancin in Elastomeric Pumps()
por: Sand, Patrick, et al.
Publicado: (2015)

Knowledge and Attitudes about Antibiotics and Antibiotic Resistance of 2404 UK Healthcare Workers
por: Ashiru-Oredope, Diane, et al.
Publicado: (2022)

1555. Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin–Tazobactam and Vancomycin Compared with Those on Piperacillin–Tazobactam and Telavancin
por: Reilly, Joseph, et al.
Publicado: (2019)

Efficacy of telavancin for treatment of surgical site infections
por: Wilson, SE, et al.
Publicado: (2008)

Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles, et al.
Publicado: (2017)

Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Reilly, Joseph, et al.
Publicado: (2020)

Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles R., et al.
Publicado: (2021)

Role of telavancin in treatment of skin and skin structure infections
por: Bonkowski, Joseph, et al.
Publicado: (2010)

Update on the emerging role of telavancin in hospital-acquired infections
por: Nnedu, Obinna N, et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
por: al Jalali, Valentin, et al.
Publicado: (2018)

2364. Evaluation of Renal Function Changes in Patients With Prolonged Telavancin Therapy (>21 Days): Results From the Telavancin Observational Use Registry (TOUR™)
por: Hassoun, Ali, et al.
Publicado: (2018)

Recurrence of skin infections in patients treated with telavancin versus vancomycin for complicated skin and soft tissue infections in a New Orleans emergency department
por: Dunbar, L, et al.
Publicado: (2008)

2369. Clinical Experience With Telavancin for Treatment of Patients With Monomicrobial S. aureus Infections (Vancomycin MIC ≥1 μg/mL) From TOUR™
por: Jacobs, Micah, et al.
Publicado: (2018)

Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials
por: Nogid, Boris, et al.
Publicado: (2018)

Evolutionary conservation of motifs within vanA and vanB of vancomycin-resistant enterococci
por: Memili, Aylin, et al.
Publicado: (2022)

Evaluation of telavancin dose capping in a large community hospital
por: Hassoun, Ali, et al.
Publicado: (2017)

Anatomical variations of the recurrent laryngeal nerve in Chinese patients: a prospective study of 2,404 patients
por: Shao, Tanglei, et al.
Publicado: (2016)

2404. Widespread emergence of infective endocarditis due to Serratia spp.: Results of a large multicenter cohort
por: Madeline McCrary, L, et al.
Publicado: (2023)

Safety and Efficacy of Telavancin at an Outpatient Parenteral Antibiotic Therapy (OPAT) Unit in New York City
por: Rodriguez, George D, et al.
Publicado: (2017)

Guidelines on postoperative magnetic resonance imaging in patients operated for cryptoglandular anal fistula: Experience from 2404 scans
por: Garg, Pankaj, et al.
Publicado: (2021)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Evaluation of GeneXpert vanA/vanB in the early diagnosis of vancomycin-resistant enterococci infection
por: Li, Zhuo-Lei, et al.
Publicado: (2021)

Structural and Functional Adaptation of Vancomycin Resistance VanT Serine Racemases
por: Meziane-Cherif, Djalal, et al.
Publicado: (2015)

Vancomycin does not affect the enzymatic activities of purified VanS(A)
por: Upton, Elizabeth C., et al.
Publicado: (2019)

Frequency of VanA, VanB and VanH variants amongst vancomycin-resistant enterococci isolated from patients in central region of Iran
por: Rezvani, Jaafar, et al.
Publicado: (2016)

735. Vancomycin-Resistant vanB- and vanA/vanB-type Enterococcus faecium Causing Invasive Infections in Adult Patients in Chile
por: Diaz, Lorena, et al.
Publicado: (2023)

GNPTAB c.2404C > T nonsense mutation in a patient with mucolipidosis III alpha/beta: a case report
por: Ho, Chi-Chun, et al.
Publicado: (2018)

Incidence rate of injury and injury sites in European and Swiss karate competitions: a prospective epidemiological study of 2404 fights
por: Rosso, Claudio, et al.
Publicado: (2023)

PB2404: ASSOCIATION OF P14ARF EXPRESSION WITH THE RISK OF PROGRESSION AND DEATH IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Sarpova, Maria, et al.
Publicado: (2023)

Hydrodynamics of the VanA-type VanS histidine kinase: an extended solution conformation and first evidence for interactions with vancomycin
por: Phillips-Jones, Mary K., et al.
Publicado: (2017)

Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections
por: Jafari Saraf, Lida, et al.
Publicado: (2011)

Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
por: Hooper, Candace Y, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_f2hnfqv0llmppslbtnkp944tt2